Psychedelics Today

Download In this episode Kyle and Joe sit down and discuss Esketamine, a new FDA approved drug that is a derivative of Ketamine. They invite quotes from professionals who have experience with generic Ketamine and to voice their opinions. 3 Key Points: Janssen Pharmaceutica has announced an FDA approved derivative of Ketamine, Esketamine, called Spravato. The new drug is facing critique on its pricing, route of administration as well as functional differences when compared to the traditional, generic Ketamine. Joe and Kyle invite professionals in the field who have experience with generic Ketamine to voice their opinions, hopes and concerns about Spravato. Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Trip Journal                                               Integration Workbook             Show Notes Esketamine Janssen Pharm